The UK-based company has established a novel drug discovery and RNA analytics platform which allows for the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections and CNS diseases.

STORM’s lead program STC-15 is a first-in-class clinical candidate, for which an IND has been filed with the US Food and Drug Administration to support initiation of a Phase I oncology trial in the second half of 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans.